DRMAW
Dermata Therapeutics, Inc.
Set alert
- YTD
- -96.81%
- 1 year
- -96.81%
- Open
- 0.0229
- Prev close
- 0.0012
- Mkt cap
- 409
- Vol
- 146.06K
- Avg vol
- 0
- EPS
- -2.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0005
- High
- 0.0011
- Forward P/E
- 0.00
- Beta
- 0.79
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
News
-
7 months ago benzinga.com
Dermata Therapeutics Secures Australian Patent Acceptance For Bioneedle System In Dermal Fillers
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has allowed and issued patents in the US,…
-
10 months ago benzinga.com
Dermata Therapeutics Announces Private Placement Up To $12.4M
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements…
11 months ago accessnewswire.com
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today…
-
1 year ago benzinga.com
Dermata Therapeutics Announces Australian Patent Office Accept Patent Application For Spongilla Technology Combination As Method For Treating Acne
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -- Dermata expects to launch a new once-weekly,…
-
1 year ago benzinga.com
Dermata Therapeutics Announces Strategic Pivot To Prioritize Development And Distribution Of OTC Pharmaceutical Dermatology Focused Products
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the…
-
1 year ago benzinga.com
Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference At 4 Weeks
- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -- Additional data analysis revealed that…